| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Nanoscience & Nanotechnology |
| Manuscript Type |
Minireviews |
| Article Title |
Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Virna Margarita Martín Giménez, Sebastián García Menéndez, Raúl Lelio Sanz, Máximo Schiavone, Leon Ferder, Felipe Inserra and Walter Manucha |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación |
PICT 2020 Serie A 4000 |
|
| Corresponding Author |
Walter Manucha, PhD, Professor, Department of Pathology, Instituto de Medicina y Biología Experimental de Cuyo, Consejo Nacional de Investigación Científica y Tecnológica Universidad Nacional de Cuyo, Laboratorio de Farmacología Experimental Básica y Traslacional, Facultad de Ciencias Médicas, Farmacología, Mendoza 5500, Argentina. wmanucha@yahoo.com.ar |
| Key Words |
Neuroinflammation; Nanotechnology/nanopharmacology; Blood-brain barrier; Oxidative stress; Neurodegeneration; Hypertension; Metabolic disorders |
| Core Tip |
This mini-review unveils the intricate nexus between hypertension, metabolic disorders, and neurodegeneration, spotlighting neuroinflammation as a pivotal mediator. To highlight, the compromised cerebral blood flow and blood-brain barrier (BBB) disruption initiate a cascade of oxidative stress and pro-inflammatory cytokine release, culminating in neuronal injury. Crucially, we advocate for the transformative potential of nanopharmacology. Nanoparticle-mediated drug delivery offers a strategic avenue to enhance therapeutic bioavailability and selectivity, enabling targeted intervention across the BBB. By synergizing effective blood pressure management with nanotechnology-driven modulation of neuroinflammation, we pioneer novel strategies to mitigate neurodegenerative pathologies. This paradigm shift holds promise for revolutionizing therapeutic approaches, paving the way for improved patient outcomes in hypertension-associated neurological disorders. |
| Publish Date |
2025-08-12 08:18 |
| Citation |
<p>Martín Giménez VM, García Menéndez S, Sanz RL, Schiavone M, Ferder L, Inserra F, Manucha W. Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders. <i>World J Exp Med</i> 2025; 15(3): 106743</p> |
| URL |
https://www.wjgnet.com/2220-315X/full/v15/i3/106743.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v15.i3.106743 |
